MARKET

EWTX

EWTX

Edgewise Therapeutics, Inc.
NASDAQ
45.93
+0.11
+0.24%
After Hours: 45.93 0 0.00% 19:30 11/13 EST
OPEN
45.72
PREV CLOSE
45.82
HIGH
46.75
LOW
44.08
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
48.78
52 WEEK LOW
16.98
MARKET CAP
5.03B
P/E (TTM)
5.61
1D
5D
1M
3M
1Y
5Y
1D
Is Edgewise Therapeutics (EWTX) Undervalued As EDG 7500 Moves Toward Phase 3?
Simply Wall St · 19h ago
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire · 5d ago
Edgewise Therapeutics’ Buy Rating Reaffirmed on Encouraging EDG-7500 Data and $57 Price Target
TipRanks · 5d ago
Weekly Report: what happened at EWTX last week (1102-1106)?
Weekly Report · 5d ago
Edgewise Therapeutics Stock Gains Attention After Phase 3 Trial Plan Submission
Simply Wall St · 6d ago
Is Edgewise Therapeutics (EWTX) Undervalued After Positive FDA Feedback For EDG 7500?
Simply Wall St · 11/07 01:22
Edgewise Therapeutics gains amid report of takeover interest
Seeking Alpha · 11/06 16:47
Edgewise Therapeutics rumor highlighted in Betaville blog
TipRanks · 11/06 16:40
More
About EWTX
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).

Webull offers Edgewise Therapeutics Inc stock information, including NASDAQ: EWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EWTX stock methods without spending real money on the virtual paper trading platform.